Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 4

Response to first-line treatment according to the chemotherapy regimen.

Response		First-line chemotherapy regimen				Total
		Nab-paclitaxel-gemcitabine	FOLFIRINOX/CAPOXIRI	Gemcitabine	Others
CR	N (%)	5	1	0	0	6
		5.5	2.6	0.0	0.0	3.8
PR	N (%)	39	12	1	4	56
		42.9	31.6	10.0	22.2	35.7
SD	N (%)	28	13	3	10	54
		30.8	34.2	30.0	55.6	34.4
PD	N (%)	19	12	6	4	41
		20.9	31.6	60.0	22.2	26.1
Total	N (%)	91	38	10	18	157
		58.0	24.2	6.4	11.4	100.0

CAPOXIRI, oxaliplatin/irinotecan/capecitabine; CR, complete response; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; PD, progressive disease; PR, partial response; SD, stable disease.